Inhibition of the turnover of the brain dopamine after treatment with the gammaaminobutyrate: 2-oxyglutarate transaminase inhibitor aminooxyacetic acid.
D000085:Acetates / Q000494:pharmacology*; D000613:Aminobutyrates; D000818:Animals; D001921:Brain / Q000201:enzymology / Q000378:metabolism*; D001923:Brain Chemistry / Q000187:drug effects; D003342:Corpus Striatum / Q000378:metabolism; D004298:Dopamine / Q000032:analysis / Q000378:metabolism; D018492:Dopamine Antagonists; D006220:Haloperidol / Q000494:pharmacology; D006885:Hydroxybutyrates / Q000494:pharmacology; D006898:Hydroxylamines / Q000494:pharmacology; D008032:Limbic System / Q000378:metabolism; D008297:Male; D008781:Methyltyrosines / Q000494:pharmacology; D009638:Norepinephrine / Q000032:analysis / Q000378:metabolism; D051381:Rats; D000637:Transaminases / Q000037:antagonists & inhibitors*
D000085:Acetates; D000613:Aminobutyrates; D018492:Dopamine Antagonists; D006885:Hydroxybutyrates; D006898:Hydroxylamines; D008781:Methyltyrosines; D000637:Transaminases; D006220:Haloperidol; D004298:Dopamine; D009638:Norepinephrine